<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00487578</url>
  </required_header>
  <id_info>
    <org_study_id>106542</org_study_id>
    <nct_id>NCT00487578</nct_id>
  </id_info>
  <brief_title>Naratriptan for the Treatment of Post Traumatic Headache Associated With Cognitive Dysfunction</brief_title>
  <official_title>Evaluation of the Efficacy of Naratriptan for the Treatment and Prevention of Post Traumatic Headache Associated With Cognitive Dysfunction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cady, Roger, M.D.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Clinvest</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Cady, Roger, M.D.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether naratriptan, a medication approved for
      treatment of migraine, is effective in the treatment of post traumatic headache associated
      with cognitive dysfunction.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Naratriptan has demonstrated efficacy in relieving headache. Other studies have demonstrated
      that primary headaches with at least one headache feature are likely to respond to triptans.
      In addition, there are anecdotal reports of triptans being effective in post traumatic
      headaches, especially if headache features are noted in the patient's history. Further, there
      are several small pilot studies with triptans demonstrating a prompt improvement in
      headache-induced cognitive changes. Cognitive performance can be measured by the Mental
      Efficiency Workload Test (MEWT), a handheld Palm neuropsychological test battery that
      measures mental efficiency. This tool can be used to demonstrate short and long term
      improvement in mental status beyond that seen at baseline.

      Informal observations by the protocol authors have suggested that the use of triptans on a
      routine basis may ameliorate the headache and associated symptomatology of post traumatic
      headache. Therefore, this study is undertaken to study the use of naratriptan in the
      treatment of post traumatic headache. Roger K. Cady, MD, serves as the sponsor. The study is
      funded by GlaxoSmithKline.

      56 subjects with a formal diagnosis of Chronic post-traumatic headache attributed to mild
      head injury (IHS/ICHD-II 5.2.2) and with self-reported mild cognitive inefficiency secondary
      to headache will be enrolled. Subjects meeting inclusion criteria will complete a physical
      examination and baseline testing and be randomized 1:1 to naratriptan 2.5mg bid x 30 days or
      a matched placebo bid x 30 days. A daily diary will document response to treatment. Subjects
      will return to the clinic at Day 10 and Day 30 and complete phone contacts at Days 5, 15, 21,
      32 and 90. Information will be collected throughout the study on questionnaires related to
      headache impact, general health, satisfaction with medication, and quality of life. Cognition
      will be measured using the MEWT.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Terminated October 2009 (in 4th year) due to low enrollment and anticipated drug expiration
    November 2009.
  </why_stopped>
  <start_date>October 2006</start_date>
  <completion_date type="Actual">October 2009</completion_date>
  <primary_completion_date type="Actual">October 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Headache Days</measure>
    <time_frame>Day 30</time_frame>
    <description>Number of headache days as measured by the Headache Diary</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Headache Impact Test-6 (HIT-6) Score</measure>
    <time_frame>Day 0, Day 30</time_frame>
    <description>Impact of headache symptoms on subject's life as measured by HIT-6 questionnaire scores. Possible scores range from 36 to 78. Score of 48 or less indicates headache has little impact on life. Score of 60-78 indicative of very severe impact.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mental Efficiency Workload Test (MEWT) Performance Index Score</measure>
    <time_frame>Day 0, Day 10, Day 30</time_frame>
    <description>Cognitive function as measured by Performance Index scores on the Mental Efficiency Workload Test (MEWT). On the performance index scale of 1 to 10, 1 indicates the poorest level and 10 indicates the best level of cognitive functioning. Tests include: Simple reaction time, Running memory, Matching to sample, Math processing and a sleep scale.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Satisfaction With Medication Score</measure>
    <time_frame>Day 30, Day 90</time_frame>
    <description>Subject overall satisfaction with effectiveness of the therapy as measured by score on the Satisfaction with Medication questionnaire. Scale range: Very satisfied, Satisfied, Neutral, Dissatisfied, Very dissatisfied.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life Scores</measure>
    <time_frame>Day 0, Day 30, Day 90</time_frame>
    <description>Quality of life as measured by Migraine Specific Quality of Life questionnaire (MSQ) scores. 14 questions ask how often headaches have interfered with specific daily activities in previous 4 weeks. 6-point scale ranges from &quot;None of the time&quot; to &quot;All of the time&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sustained Treatment Effect</measure>
    <time_frame>Day 0, Day 10, Day 30</time_frame>
    <description>Sustained treatment effect as measured by the MEWT Performance Index score compared to change in number of Headache Days. Results would be presented in the form of a correlation analysis. There is an expected negative correlation as performance index increases and number of headache days decrease (a correlation of -1).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Post Traumatic Headache</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Naratriptan 2.5 mg tablet bid x 30 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo matching naratriptan 2.5 mg tablet</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>naratriptan HCl</intervention_name>
    <description>naratriptan 2.5mg tablet bid x 30 days OR matching placebo</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
    <other_name>Amerge</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males and females between the ages of 18-55. A female is eligible to enter and
             participate if she is of: non-childbearing potential (i.e., physiologically incapable
             of becoming pregnant); or, child-bearing potential, has a negative pregnancy test
             (urine or serum) at screen, and agrees to one of the following: Complete abstinence
             from intercourse from 2 weeks prior to administration of the investigational product,
             throughout the study, and for a time interval (5 days) after completion or premature
             discontinuation from the study; subjects utilizing this method must agree to use
             alternate method of contraception if they become sexually active and will be queried
             on whether they have been abstinent when they present to the clinic for the Final
             Visit or, Female sterilization; or, Sterilization of male partner; or, Implants of
             levonorgestrel; or, Injectable progestogen; or, Oral contraceptive (combined or
             progestogen only); or, Any intrauterine device (IUD) with published data showing
             highest expected failure rate is less than 1% per year (not all IUDs meet this
             criterion); or, Spermicide plus a mechanical barrier (e.g., spermicide plus a male
             condom or a female diaphragm). Any other barrier methods (only if used in combination
             with any of the above acceptable methods) or, Any other methods with published data
             showing highest expected failure rate for that method is less than 1% per year.

          -  Formally diagnosed ICHD 5.2.2 chronic post traumatic headache

          -  Have had traumatic brain injury (TBI) not more than 5 years prior to enrollment

          -  Medically stable as determined by Investigator

          -  On stabilized dosage of any headache preventive medications for 3 months prior to
             screening

          -  On stabilized dosage of concomitant medications at discretion of investigator

          -  Chronic headache history only after the TBI

          -  Able to understand and communicate intelligibly with study observer

          -  Able to take oral medication, adhere to the medication regimens and perform study
             procedures

          -  Able to read and comprehend written instructions and be willing to complete all
             procedures and assessments required by protocol

          -  Subject is able to demonstrate willingness to participate by signing and understanding
             an informed consent after full explanation of study

          -  Self-reported cognitive inefficiency or &quot;brain-fog&quot; during headache

        Exclusion Criteria:

          -  History of hypersensitivity to triptan-like medication

          -  Pathology of salivary glands such as sialadenitis (e.g., Sjorgen's Syndrome, viral or
             bacterial sialadenitis, or obstructive sialadenitis)

          -  Any condition or symptom that would knowingly alter content of saliva

          -  History of, symptoms or signs of ischemic cardiac, cerebrovascular or peripheral
             vascular syndromes or other significant underlying cardiovascular disease. Ischemic
             cardiac syndromes include, but are not limited to, angina pectoris of any type (e.g.
             stable angina of effort and vasospastic forms of angina such as Prinzmetal variant,
             all forms of myocardial infarction, and silent myocardial ischemia. Cerebrovascular
             syndromes include, but are not limited to, strokes of any type as well as transient
             ischemic attacks. Peripheral vascular disease includes, but is not limited to,
             ischemic bowel disease.

          -  Any medication overuse that in the opinion of the investigator has exacerbated or
             contributed to current headache pattern of subject

          -  Uncontrolled hypertension, severe renal impairment, severe hepatic impairment,
             hemiplegic or basilar headache

          -  History of hypersensitivity to naratriptan or any components

          -  Pregnant, trying to get pregnant, or lactating

          -  Recent history of abuse of alcohol or other drugs that would interfere with
             participation

          -  Participation in another investigative drug study within previous 30 days

          -  Chronic pain syndromes, fibromyalgia, Gulf War Syndrome, and other multisystem
             diseases characterized by poor or no response to pain-reducing interventions
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roger K Cady, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinvest</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinvest</name>
      <address>
        <city>Springfield</city>
        <state>Missouri</state>
        <zip>65807</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carolinas Rehabilitation, Carolinas HealthCare System</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Anodyne Headache and Pain Care</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Baandrup L, Jensen R. Chronic post-traumatic headache--a clinical analysis in relation to the International Headache Classification 2nd Edition. Cephalalgia. 2005 Feb;25(2):132-8. Erratum in: Cephalalgia. 2005 Mar;25(3):240.</citation>
    <PMID>15658950</PMID>
  </reference>
  <reference>
    <citation>Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders: 2nd edition. Cephalalgia. 2004;24 Suppl 1:9-160.</citation>
    <PMID>14979299</PMID>
  </reference>
  <verification_date>February 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 14, 2007</study_first_submitted>
  <study_first_submitted_qc>June 14, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 18, 2007</study_first_posted>
  <results_first_submitted>November 16, 2009</results_first_submitted>
  <results_first_submitted_qc>January 12, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 2, 2010</results_first_posted>
  <last_update_submitted>February 4, 2013</last_update_submitted>
  <last_update_submitted_qc>February 4, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 11, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Post traumatic headache</keyword>
  <keyword>Head trauma</keyword>
  <keyword>Head injury</keyword>
  <keyword>Headache</keyword>
  <keyword>Naratriptan</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Headache</mesh_term>
    <mesh_term>Cognitive Dysfunction</mesh_term>
    <mesh_term>Post-Traumatic Headache</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Naratriptan</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subject enrollment started in 2006 at Site 1 (headache specialty clinic). Subjects were never enrolled at 2nd site (hospital rehabilitation center). Sites 3 (pain clinic) and 4 (hospital rehabilitation center) were added in 2008. Enrollment continued until study termination October 2009.</recruitment_details>
      <pre_assignment_details>19 participants were screened. 7 were Screen Failures.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Active Naratriptan</title>
          <description>Naratriptan 2.5 mg tablet twice daily (bid) x 30 days</description>
        </group>
        <group group_id="P2">
          <title>Placebo Matching Naratriptan</title>
          <description>placebo matching naratriptan 2.5 mg tablet twice daily (bid) x 30 days</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Active Naratriptan</title>
          <description>Naratriptan 2.5 mg tablet twice daily (bid) x 30 days</description>
        </group>
        <group group_id="B2">
          <title>Placebo Matching Naratriptan</title>
          <description>placebo matching naratriptan 2.5 mg tablet twice daily (bid) x 30 days</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="3"/>
            <count group_id="B2" value="9"/>
            <count group_id="B3" value="12"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39.66" spread="10.96"/>
                    <measurement group_id="B2" value="37.22" spread="9.65"/>
                    <measurement group_id="B3" value="37.83" spread="9.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Headache Days</title>
        <description>Number of headache days as measured by the Headache Diary</description>
        <time_frame>Day 30</time_frame>
        <population>No analysis was conducted. Study terminated due to expiration of study medication and low enrollment.</population>
        <group_list>
          <group group_id="O1">
            <title>Active Naratriptan</title>
            <description>Naratriptan 2.5 mg tablet twice daily (bid) x 30 days</description>
          </group>
          <group group_id="O2">
            <title>Placebo Matching Naratriptan</title>
            <description>placebo matching naratriptan 2.5 mg tablet twice daily (bid) x 30 days</description>
          </group>
        </group_list>
        <measure>
          <title>Headache Days</title>
          <description>Number of headache days as measured by the Headache Diary</description>
          <population>No analysis was conducted. Study terminated due to expiration of study medication and low enrollment.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Headache Impact Test-6 (HIT-6) Score</title>
        <description>Impact of headache symptoms on subject's life as measured by HIT-6 questionnaire scores. Possible scores range from 36 to 78. Score of 48 or less indicates headache has little impact on life. Score of 60-78 indicative of very severe impact.</description>
        <time_frame>Day 0, Day 30</time_frame>
        <population>No analysis was conducted. Study terminated due to expiration of study medication and low enrollment.</population>
        <group_list>
          <group group_id="O1">
            <title>Active Naratriptan</title>
            <description>Naratriptan 2.5 mg tablet twice daily (bid) x 30 days</description>
          </group>
          <group group_id="O2">
            <title>Placebo Matching Naratriptan</title>
            <description>placebo matching naratriptan 2.5 mg tablet twice daily (bid) x 30 days</description>
          </group>
        </group_list>
        <measure>
          <title>Headache Impact Test-6 (HIT-6) Score</title>
          <description>Impact of headache symptoms on subject's life as measured by HIT-6 questionnaire scores. Possible scores range from 36 to 78. Score of 48 or less indicates headache has little impact on life. Score of 60-78 indicative of very severe impact.</description>
          <population>No analysis was conducted. Study terminated due to expiration of study medication and low enrollment.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mental Efficiency Workload Test (MEWT) Performance Index Score</title>
        <description>Cognitive function as measured by Performance Index scores on the Mental Efficiency Workload Test (MEWT). On the performance index scale of 1 to 10, 1 indicates the poorest level and 10 indicates the best level of cognitive functioning. Tests include: Simple reaction time, Running memory, Matching to sample, Math processing and a sleep scale.</description>
        <time_frame>Day 0, Day 10, Day 30</time_frame>
        <population>No analysis was conducted. Study terminated due to expiration of study medication and low enrollment.</population>
        <group_list>
          <group group_id="O1">
            <title>Active Naratriptan</title>
            <description>Naratriptan 2.5 mg tablet twice daily (bid) x 30 days</description>
          </group>
          <group group_id="O2">
            <title>Placebo Matching Naratriptan</title>
            <description>placebo matching naratriptan 2.5 mg tablet twice daily (bid) x 30 days</description>
          </group>
        </group_list>
        <measure>
          <title>Mental Efficiency Workload Test (MEWT) Performance Index Score</title>
          <description>Cognitive function as measured by Performance Index scores on the Mental Efficiency Workload Test (MEWT). On the performance index scale of 1 to 10, 1 indicates the poorest level and 10 indicates the best level of cognitive functioning. Tests include: Simple reaction time, Running memory, Matching to sample, Math processing and a sleep scale.</description>
          <population>No analysis was conducted. Study terminated due to expiration of study medication and low enrollment.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Satisfaction With Medication Score</title>
        <description>Subject overall satisfaction with effectiveness of the therapy as measured by score on the Satisfaction with Medication questionnaire. Scale range: Very satisfied, Satisfied, Neutral, Dissatisfied, Very dissatisfied.</description>
        <time_frame>Day 30, Day 90</time_frame>
        <population>No analysis was conducted. Study terminated due to expiration of study medication and low enrollment.</population>
        <group_list>
          <group group_id="O1">
            <title>Active Naratriptan</title>
            <description>Naratriptan 2.5 mg tablet twice daily (bid) x 30 days</description>
          </group>
          <group group_id="O2">
            <title>Placebo Matching Naratriptan</title>
            <description>placebo matching naratriptan 2.5 mg tablet twice daily (bid) x 30 days</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Satisfaction With Medication Score</title>
          <description>Subject overall satisfaction with effectiveness of the therapy as measured by score on the Satisfaction with Medication questionnaire. Scale range: Very satisfied, Satisfied, Neutral, Dissatisfied, Very dissatisfied.</description>
          <population>No analysis was conducted. Study terminated due to expiration of study medication and low enrollment.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Life Scores</title>
        <description>Quality of life as measured by Migraine Specific Quality of Life questionnaire (MSQ) scores. 14 questions ask how often headaches have interfered with specific daily activities in previous 4 weeks. 6-point scale ranges from &quot;None of the time&quot; to &quot;All of the time&quot;.</description>
        <time_frame>Day 0, Day 30, Day 90</time_frame>
        <population>No analysis was conducted. Study terminated due to expiration of study medication and low enrollment.</population>
        <group_list>
          <group group_id="O1">
            <title>Active Naratriptan</title>
            <description>Naratriptan 2.5 mg tablet twice daily (bid) x 30 days</description>
          </group>
          <group group_id="O2">
            <title>Placebo Matching Naratriptan</title>
            <description>placebo matching naratriptan 2.5 mg tablet twice daily (bid) x 30 days</description>
          </group>
        </group_list>
        <measure>
          <title>Quality of Life Scores</title>
          <description>Quality of life as measured by Migraine Specific Quality of Life questionnaire (MSQ) scores. 14 questions ask how often headaches have interfered with specific daily activities in previous 4 weeks. 6-point scale ranges from &quot;None of the time&quot; to &quot;All of the time&quot;.</description>
          <population>No analysis was conducted. Study terminated due to expiration of study medication and low enrollment.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sustained Treatment Effect</title>
        <description>Sustained treatment effect as measured by the MEWT Performance Index score compared to change in number of Headache Days. Results would be presented in the form of a correlation analysis. There is an expected negative correlation as performance index increases and number of headache days decrease (a correlation of -1).</description>
        <time_frame>Day 0, Day 10, Day 30</time_frame>
        <population>No analysis was conducted. Study terminated due to expiration of study medication and low enrollment.</population>
        <group_list>
          <group group_id="O1">
            <title>Active Naratriptan</title>
            <description>Naratriptan 2.5 mg tablet twice daily (bid) x 30 days</description>
          </group>
          <group group_id="O2">
            <title>Placebo Matching Naratriptan</title>
            <description>placebo matching naratriptan 2.5 mg tablet twice daily (bid) x 30 days</description>
          </group>
        </group_list>
        <measure>
          <title>Sustained Treatment Effect</title>
          <description>Sustained treatment effect as measured by the MEWT Performance Index score compared to change in number of Headache Days. Results would be presented in the form of a correlation analysis. There is an expected negative correlation as performance index increases and number of headache days decrease (a correlation of -1).</description>
          <population>No analysis was conducted. Study terminated due to expiration of study medication and low enrollment.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>90 days</time_frame>
      <desc>AEs collected from Diaries reviewed at Visit 2/Day 10 and Visit 3/Day 30. AEs collected during phone interviews (Days 5, 15, 21, 32, and 90).</desc>
      <group_list>
        <group group_id="E1">
          <title>Active Naratriptan</title>
          <description>Naratriptan 2.5 mg tablet twice daily (bid) x 30 days</description>
        </group>
        <group group_id="E2">
          <title>Placebo Matching Naratriptan</title>
          <description>placebo matching naratriptan 2.5 mg tablet twice daily (bid) x 30 days</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>literal CRF term</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Blurred vision</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>nausea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Reflux</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Referred to cardiologist. Stress ECG performed. All normal. Pt unblinded.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Stomach tenderness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Twitching eye</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Increased twitching left arm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Sweating</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Itching eyes</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Feels hot and cold</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Unbalanced gait</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>low back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Achiness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Leg cramps</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Increased headache severity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Change in headache location</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Change in headache sensation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Increased headache frequency</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Drowsiness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Tingling</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Burning sensation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Itching neck</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Redness of face</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Publication of study data collected by Investigator is authorized subject to the following:Investigator is free to publish results of its part of study in collaboration with other investigators subsequent to the multicenter publication issued by Clinvest. If no multicenter publication is submitted within 12 months of end of study, investigator may publish results of its data. Investigator shall submit a copy of manuscript or abstract to Clinvest for review 30 days prior to journal submission.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Study terminated October 2009 (in 4th year) due to low enrollment and anticipated drug expiration November 2009 (study drug had previously been re-supplied at expiration of 1st batch November 2007).
No analysis performed.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>M.E. Beach</name_or_title>
      <organization>Clinvest</organization>
      <phone>(417) 841-3618</phone>
      <email>mbeach@clinvest.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

